• In addition, a deeper characterization of immune infiltrates, including the presence of a high number of cytotoxic (CD8 + ) TILs or a high CD8 + /FOXP3 + ratio, is able to define TNBC patients with a better prognosis following neoadjuvant chemotherapy [ 6 ]. (biomedcentral.com)
  • Conclusion: It could be concluded that diagnostic laparoscopy is accurate staging tool for gastro intestinal tumors as staging method prior to surgery that can change plan to start neoadjuvant chemotherapy (CTR) instead of surgery. (bvsalud.org)
  • Subsequent complete surgical resection of the tumor is usually followed by postoperative, adjuvant chemotherapy ( 3 ). (iiarjournals.org)
  • Kobayashi M, Tsuburaya A, Nagata N, Miyashita Y, Oba K, Sakamoto J. A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. (u-tokyo.ac.jp)
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer. (nccn.org)
  • Of particular interest are adjuvant therapy, treatment of metastatic disease, methods for treatment of locally advanced breast cancer and inflammatory breast cancer. (stanford.edu)
  • It is not yet known whether chemotherapy is effective in treating women who have undergone surgery and radiation therapy for relapsed breast cancer. (stanford.edu)
  • The 2018 publication of the TAILORx trial helped refine the use of genetic expression assays, specifically the 21-gene recurrence score, in assigning patients to endocrine therapy alone or with chemotherapy. (jnccn.org)
  • One of the greatest practice-changing trials of my entire career was the IDEA study , now presented at the ASCO annual meeting more than 5 years ago, which looked at outcomes based on 3 vs 6 months of oxaliplatin-containing adjuvant therapy - whether FOLFOX or CAPOX - in stage III colon cancer. (medscape.com)
  • The rationale for neoadjuvant chemoradiation therapy (Neo-CRT) and the definition of borderline resectable pancreatic cancer (BRPC) are still controversial. (elsevierpure.com)
  • 0.001), pT stage (P = 0.001), pTNM stage (P = 0.002), combined vascular resection (P = 0.003), completeness of adjuvant therapy (P = 0.004) were found to be statistically significantly different between Groups 1 and 2. (elsevierpure.com)
  • These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. (nccn.org)
  • This approach is based on the rationale that local therapy through the hepatic artery increases the exposure of the liver tumors to cytotoxic agents, leading to higher response rates while limiting systemic side effects like myelosuppression, mucositis and diarrhea. (biomedcentral.com)
  • Osteosarcoma is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy. (sarcomahelp.org)
  • Most patients with high grade tumors receive about three months of chemotherapy, known as neo-adjuvant therapy, before surgery. (sarcomahelp.org)
  • and the Intergroup Exemestane Study (IES), in which patients with early breast cancer were either switched to exemestane or continued on tamoxifen adjuvant therapy. (drugtopics.com)
  • Adjuvant therapy following curative surgery has significantly improved breast cancer outcome. (allianceforclinicaltrialsinoncology.org)
  • At a median follow-up of 120 months in patients enrolled in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, recurrence was observed in 19.7 percent and 24.0 percent of patients treated with five years of adjuvant anastrozole and tamoxifen, respectively, with a persistent risk of relapse over time observed in both treatment arms, indicating a need to improve the current standard therapy. (allianceforclinicaltrialsinoncology.org)
  • By providing validated surrogate endpoints for endocrine therapy agents and the response data (pCR rate) to standard chemotherapy for the resistant population, results from this study are expected to provide the foundation for future novel therapeutics development for early stage ER+ breast cancer. (allianceforclinicaltrialsinoncology.org)
  • analyzing the velocity (i.e., the change over time) of the markers, malignancy we could stipulate for each patient the risk of developing metas- tasis after the end of adjuvant systemic therapy. (lu.se)
  • The rationale for combination therapy is to use drugs that work by different mechanisms, thereby decreasing the likelihood that resistant cancer cells will develop. (msdmanuals.com)
  • Radiation therapy and/or drug therapy given after surgery (called adjuvant therapy) help to destroy any remaining cancer cells. (msdmanuals.com)
  • We are conducting a phase III randomised trial to determine if the addition of the anti-PD-L1 antibody avelumab following adjuvant chemotherapy improves disease-free survival (DFS) in patients with stage III dMMR/MSI-H or POLE mutant colon cancer and is a cost-effective approach for the UK National Health Service (NHS). (ox.ac.uk)
  • Eligible patients are randomised in a 1:1 ratio to standard fluoropyrimidine-based chemotherapy (capecitabine, oxaliplatin for 12 weeks or capecitabine for 24 weeks) or chemotherapy, followed by avelumab (10 mg/kg, 2 weekly for 24 weeks). (ox.ac.uk)
  • Is there a rationale for aggressive breast cancer liver metastases resections in Polish female patients? (aaem.pl)
  • Oncological centres should assess BCLM patients more openly and qualify them for hepatic resection along with adjuvant systemic treatment in order to improve overall survival. (aaem.pl)
  • The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast cancer. (stanford.edu)
  • This was a massive, attention-grabbing headline around a small but significant study run by colleagues at Memorial Sloan Kettering looking at the role of dostarlimab in locally advanced, MSI-high rectal cancer, with the really remarkable finding that all of the patients in the study, although it was the low double digits in terms of the end, responded to that immunotherapy and then did not require chemotherapy, radiation, or surgery. (medscape.com)
  • The discovery that a significant number of my patients could receive half the duration of adjuvant chemotherapy, with their rates of chemotherapy-induced neuropathy being cut by two thirds, was immediately practice-changing for me and for thousands of oncologists across the country and across the world. (medscape.com)
  • this enhances the likelihood of removing all cancer cells (complete resection) and identifies patients who will require additional treatment (i.e. adjuvant chemotherapy). (wikipedia.org)
  • BACKGROUND: Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. (bvsalud.org)
  • Neutrophilic eccrine hidradenitis (NEH) is a neutrophilic dermatosis primarily affecting the eccrine glands and occurs most commonly in patients undergoing chemotherapy for a malignancy. (annals.edu.sg)
  • Patients were then planned for treatment with adjuvant nivolumab for 3 months. (bmj.com)
  • [1] Although chemotherapy has improved outcomes for patients, the marginal benefits achieved with cytotoxic agents seem to have reached a plateau. (carcinogenesis.com)
  • These data, together with the development of new therapeutic agents directed against immune checkpoint molecules, such as anti-PD-1 and anti-PD-L1 monoclonal antibodies, provide the rationale for the assessment of immunotherapeutic approaches in TNBC patients. (biomedcentral.com)
  • 11 ] demonstrated a substantial overall survival (OS) benefit in patients with PD-L1-positive (PD-L1 + ) metastatic or inoperable locally advanced TNBC through the addition of the anti-PD-L1 agent atezolizumab to first-line chemotherapy with nab-paclitaxel. (biomedcentral.com)
  • Approximately 60% of the enrolled patients (451 for each treatment arm) experienced relapse after prior adjuvant/neoadjuvant treatment, while 37% presented with de novo stage IV disease. (biomedcentral.com)
  • As we have previously written, most patients with cancer are treated with some combination of either surgery, chemotherapy, or radiation treatment. (breastoncology.com)
  • Pseudoaneurysms of the hepatic artery are a rare complication in patients with primary or secondary liver tumors treated with intra-arterial chemotherapy. (biomedcentral.com)
  • We present two patients who developed this complication after placement of a catheter system into the gastroduodenal artery and initiation of regional chemotherapy with floxuridine. (biomedcentral.com)
  • In this article we describe two patients who developed aneurysmatic cavities of the hepatic artery after regional chemotherapy with FUDR and presented with hemorrhage. (biomedcentral.com)
  • We aimed to reveal factors associated with chemotherapy use and evaluate chemotherapy's benefit in patients with stage III NPC stratified by lymph node status. (researchsquare.com)
  • Overall, 1,452 patients with stage III NPC who underwent radiotherapy with (n=1361) or without (n=91) chemotherapy were identified in the SEER database. (researchsquare.com)
  • Chemotherapy adds survival benefit in stage III NPC, especially in patients with node-positive disease. (researchsquare.com)
  • Overall, 1452 patients with stage III NPC with or without chemotherapy were analyzed. (researchsquare.com)
  • Patients with node-positive stage III NPC benefited from chemotherapy. (researchsquare.com)
  • Compared to metastatic MCC, a higher proportion of metastatic FCC patients ranged over 60 years of age, black race, treated without chemotherapy, and insurance, while the primary site was located on the right side. (hindawi.com)
  • Long-term Effects of Candesartan and Amlodipine on Cardiovascular Mortality and Morbidity in Japanese High-risk Hypertensive Patients: Rationale, Design, and Characteristics of Candesartan Antihypertensive Survival Evaluation in Japan Extension (CASE-J Ex). (u-tokyo.ac.jp)
  • More than 75% of patients with breast cancer treated with chemotherapy experience cognitive impairments (eg, memory and attention problems), commonly known as chemo-brain . (researchprotocols.org)
  • However, clinical trials testing the impact of exercise interventions on chemotherapy-induced cognitive decline in patients with cancer are lacking, and the mechanisms through which exercise could improve cognitive function are unclear. (researchprotocols.org)
  • The objective of the Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy trial is to examine the effects of HIIT on cognitive function in patients with breast cancer undergoing chemotherapy. (researchprotocols.org)
  • This 2-arm, single-center, pilot randomized controlled trial will randomize 50 patients with breast cancer undergoing chemotherapy to HIIT or attention control. (researchprotocols.org)
  • If positive, our findings will establish the pilot efficacy of HIIT on chemotherapy-induced cognitive function in patients with breast cancer, providing the foundation for future larger phase-II and phase-III trials to confirm the findings and potentially establish HIIT as a standard of care for women undergoing chemotherapy for breast cancer. (researchprotocols.org)
  • However, the evaluation of new agents in the adjuvant setting has traditionally required large number of patients and years of follow up to demonstrate the effectiveness in reducing cancer relapse and/or mortality. (allianceforclinicaltrialsinoncology.org)
  • Patients with tumor levels of Ki67 greater than 10 percent at these time points will be switched to neoadjuvant weekly paclitaxel, or other standard taxane and/or anthracycline or CMF (cyclophosphamide, methotrexate and fluorouracil) regimens to assess the rate of complete pathologic response (pCR) to chemotherapy as a secondary endpoint. (allianceforclinicaltrialsinoncology.org)
  • In NSCLC, a significant survival benefit was shown inside a Phase III study comparing the combination of pembrolizumab (anti-PD-1) and platinum/pemetrexed chemotherapy versus chemotherapy only. (icsv20.org)
  • The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. (biomedcentral.com)
  • The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. (stanford.edu)
  • RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. (stanford.edu)
  • chemotherapy is rarely indicated regardless of tumor status. (cancernetwork.com)
  • Cancer chemotherapy is based on an understanding of tumor cell growth and how drugs affect it. (medscape.com)
  • In other words, a cancer vaccine is most effective when there are minimal cancer cells in the body, such as after a cancer tumor is removed or after chemotherapy. (breastoncology.com)
  • LH-RH, human The biologic and immunological rationale to explain the efficacy of this combination is based on the ability of chemotherapy to restore an immune response through several complementary mechanisms in non-infiltrated tumors. (icsv20.org)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • To our knowledge, there are no published randomized trials explicitly designed for stage III NPC in evaluating the efficacy of chemotherapy. (researchsquare.com)
  • Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: Update of a meta-analysis. (u-tokyo.ac.jp)
  • In the past two decades, the integration of chemotherapy to radiotherapy has been considered a breakthrough for treating locoregionally advanced NPC. (researchsquare.com)
  • The primary sites were mainly located on the left side and have more possibility to receive chemotherapy and radiotherapy. (hindawi.com)
  • Despite recent advances in chemotherapy and radiotherapy for CC, surgical resection remains the primary treatment, but there are gender differences in CC treatment choices [ 3 , 4 ]. (hindawi.com)
  • PURPOSE: Randomized phase III trial to determine the effectiveness of adjuvant chemotherapy in treating women who have undergone resection for local and/or regional relapsed breast cancer. (stanford.edu)
  • Generally, clinically staged T1N + M0 and T2-T4aN(any)M0 gastric cancer requires surgical resection with adequate lymphadenectomy, together with perioperative or adjuvant chemotherapy. (frontiersin.org)
  • In April 2002 a wedge-resection was performed, followed by one cycle of adjuvant HAC with FUDR in May 2002. (biomedcentral.com)
  • The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. (stanford.edu)
  • Metastatic castration resistant prostate cancer (mCRPC) relapses due to acquired resistance to docetaxel-based chemotherapy and remains a major threat to patient survival. (univaq.it)
  • Chemotherapy offered a significant survival benefit in node-positive stage III NPC. (researchsquare.com)
  • Numerous randomized trials have shown relatively consistent results that chemotherapy combined with RT is associated with superior survival compared to when RT is used alone, for example, induction chemotherapy (IC), concurrent chemotherapy (CC), and adjuvant chemotherapy (AC) [3-14]. (researchsquare.com)
  • Many studies have shown that the completion of adjuvant chemotherapy improves the survival rate. (bvsalud.org)
  • The prevailing approach for curative intent treatment for locally advanced rectal cancer when PROSPECT began in 2012 was 5.5 weeks of pelvic chemoradiation, next was surgery with a total mesorectal excision, and finally, after recovery, adjuvant chemotherapy, typically 8 cycles of FOLFOX or 6 cycles of CAPOX. (medscape.com)
  • Complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CCRS+HIPEC) is on the verge of becoming the gold standard treatment for diffuse peritoneal seeding, for peritoneal pseudomyxoma, peritoneal mesothelioma, and peritoneal carcinomatosis originating from colorectal cancer (when disease is limited in extent) 1 , 2 , 3 , 4 , 5 . (wcrj.net)
  • Although deliberate hypotension during surgery may potentially cause organ ischaemia, in particular of the myocardium and cerebrum, it is widely used as an adjuvant. (annals.edu.sg)
  • The rationale behind their use subsequently led to application even in revision arthroplasty with great loss of bone stock, as well as in trauma surgery, for extremely comminuted fractures with poorly vascularized fragments, where traditional osteosynthesis cannot be applied. (openorthopaedicsjournal.com)
  • The use of trastuzumab in the adjuvant and metastatic treatment of breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity. (jnccn.org)
  • The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
  • For triple-negative disease, immunotherapy continues to gain traction in this challenging subtype, both in the preoperative and metastatic settings, though not yet as adjuvant treatment. (jnccn.org)
  • To modulate these phenomena, a combination of immunotherapy LH-RH, human with chemotherapy has been proposed and clinically tested. (icsv20.org)
  • Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. (ox.ac.uk)
  • Adjuvant or palliative treatment for adrenocortical carcinoma (AC) has been studied by using mitotane, cisplatin, etoposide, and doxorubicin. (medscape.com)
  • In the case of ER-positive breast cancer, systemic chemotherapy followed by endocrine treatment with tamoxifen has been shown to half the breast cancer mortality rate. (allianceforclinicaltrialsinoncology.org)
  • Chemotherapy is a form of systemic treatment that uses drugs to kill cancer. (msdmanuals.com)
  • Our review focuses on recent advances in the control and treatment of these diseases with particular reference to diagnosis, chemotherapy, vaccines, vector and environmental control. (who.int)
  • These data provide a biologic rationale for the use of a dual E-selectin/CXCR4 inhibitor as an adjuvant to taxane-based chemotherapy in men with mCRPC to prevent and reduce bone metastases. (univaq.it)
  • Over the past two decades, there have been advances in chemotherapy, development of FOLFOX, surgical techniques with total mesorectal excision, dissemination of screening leading to fewer T4 and large symptomatic tumors, and pelvic MRI, increasing the accuracy of staging. (medscape.com)
  • those with receptor-negative tumors may be treated with single-agent chemotherapy or supportive care measures. (cancernetwork.com)
  • Since the early 2010s, many immunotherapies based on the inhibition of immune-response control points have been developed and shown to be therapeutically superior to conventional chemotherapy. (icsv20.org)
  • The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
  • Trials include participation in the national breast cancer study groups, ECOG and NSABP, as well as the development of new chemotherapy programs. (stanford.edu)
  • In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
  • Chemotherapy and Other Systemic Cancer Treatments Systemic treatments are those that have effects throughout the body rather than being applied directly to the cancer. (msdmanuals.com)
  • Cancers such as doxorubicin are commonly used in cancer leukaemia, colorectal, breast, lung, and so on are chemotherapy. (who.int)
  • Surgical or percutaneous placement of a subcutaneous device allows chemotherapy to be delivered continuously into the gastroduodenal artery via a catheter. (biomedcentral.com)
  • Broadening our understanding will make it possible to provide rationales for the combination of chemoimmunotherapy in early medical trials. (icsv20.org)
  • The celiac angiogram shows a pseudoaneurysm (arrow) of the proper hepatic artery located next to the origin of the gastroduodenal artery, which is occluded by the chemotherapy infusion catheter (arrowheads) . (biomedcentral.com)
  • Indeed, there is an increasing body of evidence showing that chemotherapies can cause so-called immunogenic malignancy cell death (ICD) [6], which can stimulate sponsor antitumor immunity. (icsv20.org)
  • Cox regression and competing risk analyses were used to evaluate chemotherapy benefit. (researchsquare.com)
  • Dr Schrag, in her plenary presentation, did a beautiful job explaining the rationale of the PROSPECT trial . (medscape.com)
  • The effect of Neo-CRT in BRPC with IVVI may be multifactorial, providing proper patient selection, complete adjuvant chemotherapy, and potential therapeutic (downstaging) effect. (elsevierpure.com)
  • The magnitude of chemotherapy benefit in node-negative stage III NPC warrants further investigation. (researchsquare.com)
  • No chemotherapy benefit for the node-negative stage III NPC was observed. (researchsquare.com)
  • Stratification is by chemotherapy received and MMR/MSI-H status. (ox.ac.uk)